The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.
Sotyktu (deucravacitinib) for treatment of adults with active psoriatic arthritis (PsA). Sotyktu is an oral, selective ...
On the FDA’s docket this month are two decisions pushed back from 2025, including one for a rare form of obesity and another for dry eye disease.
Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...
After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...
Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for $14 billion, the companies said today, in a deal intended to bolster the buyer’s neurological drug portfolio with Karuna’s ...
Bristol Myers Squibb said in its fourth-quarter results update this morning that it will double down on an ongoing cost-cutting programme announced last year. The company still intends to slash $1.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results